BOSTON SCIENTIFIC CORP — Director's Dealing 2025

Jun 4, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2025-06-04

Reporting Person: Fitzgerald Joseph Michael (EVP & Group Pres, Cardiology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-04	Common Stock	M	56372.0000	$26.1500	Acquired	234714.0000	Direct
2025-06-04	Common Stock	S	56372.0000	$102.8814	Disposed	178342.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-04	Stock Option (Right to Buy)	$26.1500	M	56372.0000	Disposed	2027-12-01	Common Stock (56372.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5234.0000	Indirect

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.46 to $103.42, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.

F4: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.